Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 4/2021

01-04-2021 | Lennox Gastaut Syndrome | Letter to the Editor

Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”

Authors: Edward E. Neuberger, Josh J. Carlson, David L. Veenstra

Published in: PharmacoEconomics | Issue 4/2021

Login to get access

Excerpt

We thank Hollenack and Marshall [1] for their interest in our analysis, and for continuing the discussion regarding the cost effectiveness of cannabidiol (CBD) in Lennox-Gastaut Syndrome (LGS). We agree with many of the highlighted limitations, which are primarily related to data availability. …
Literature
1.
2.
Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox–Gastaut syndrome in the UK. Pharmacoeconomics. 2010;28(3):185–99.CrossRef
3.
Clements KM, Skornicki M, O’Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox–Gastaut syndrome. Epilepsy Behav. 2013;29(1):184–9.CrossRef
4.
de Kinderen RJ, Postulart D, Aldenkamp AP, et al. Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy. Epilepsy Res. 2015;110:119–31.CrossRef
5.
Elliot J, McCoy B, Clifford T, Wells G, Coyle D. Economic evaluation of stiripentol for Dravet syndrome: a cost-utility analysis. PharmacoEconomics. 2018;36(10):1253–61.CrossRef
6.
Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patientswith refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol. 1998;53:421–7.CrossRef
7.
Kristian B, Wachtmeister K, Stefan F, Forsgren L. Retigabine as add-on treatment of refractory epilepsy—a cost-utility study in a swedish setting. Acta Neurol Scand. 2013;127(6):419–26.CrossRef
8.
Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox–Gastaut Syndrome in the United Kingdom. Seizure. 2010;19(1):1–11.CrossRef
9.
Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378(20):1888–97.CrossRef
10.
Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.CrossRef
11.
Verdian L, Yi Y, Oyee J, Heyes A, Tolley K. PND22 eliciting utility scores for health states associated with Lennox–Gastaut syndrome. Value Health. 2008;11(6):A606.CrossRef
Metadata
Title
Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
Authors
Edward E. Neuberger
Josh J. Carlson
David L. Veenstra
Publication date
01-04-2021
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 4/2021
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-021-01006-9

Other articles of this Issue 4/2021

PharmacoEconomics 4/2021 Go to the issue

Original Research Article

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States

Systematic Review

Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review

Original Research Article

EQ-5D-Y Value Set for Slovenia

Editorial

Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment

Letter to the Editor

Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”

Review Article

Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision